Similarly, reactivation of the MAPK pathway without new mutations in KRAS or its downstream mediators has been reported in KRASG12C lung adenocarcinomas resistant to the KRASG12C inhibitor AMG 510 [19]. The gene discussed is KRAS; the disease is lung adenocarcinoma.